Principal Investigator(s):
Objective:This is a safety and acceptability study of the OB-002H gel which is a topical formulation of OB-002 (5P12-RANTES), a novel chemokine analogue that binds to the CCR5 receptors in order to prevent HIV infection.    Last updated: May 11, 2021
Prevention Option(s):Microbicides
Study Design:Double-blind, Open label, Placebo-controlled, Randomized
Official Code: NCT04791007
Trial Sponsors: SCOPE International AG
Start Date
End Date
October 5, 2019
August 31, 2020
Age range: 18 Years ↔ 45 Years
Population:Cisgender Women, Gay and Bisexual Men Who Have Sex with Men